Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01046825 · ClinicalTrials.gov registry record · Phase 2
Mature B-Cell Lymphoma And Leukemia Study III
A Phase 2 study of Mature B-Cell Lymphoma, sponsored by St. Jude Children's Research Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 128
- Enrollment target
- 4
- Study locations
NCT01046825: Active Phase 2 study of Mature B-Cell Lymphoma, sponsored by St. Jude Children's Research Hospital.
NCT01046825 is a Phase 2 study of Mature B-Cell Lymphoma that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 128 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01046825, a Phase 2 study of Mature B-Cell Lymphoma, is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 128 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase III clinical trial using risk-adapted therapy. Treatment outcomes for children with B-cell NHL are excellent. Further improvements in outcome will likely be achieved through more focused study of the biology of the tumors and prospective studies of the late effects of treatment. Toward this end, this study features a spectrum of prospective biologic and late effect studies performed in patients treated with a modified regimen derived from the very successful LMB-96 regimen.
Primary Outcome
Gene expression levels in BL vs. non-BL will be analyzed through approximately 22,000 probesets on the Affymetrix U133A GeneChip by using two-factor analysis of variance model for each gene.
Conditions Studied
Interventions
- DRUG COPAD
- DRUG COP, COPD M3, CYM
- DRUG COP, COPADM8, CYVE
Study Locations (4)
Other
- Children's Cancer Hospital - Cairo
- National University Health System - Singapore
California
- Rady Children's Hospital San Diego - San Diego
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2010-09-09 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
What the registry record for NCT01046825 still lists
NCT01046825 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Mature B-Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which COPAD is the first listed.
NCT01046825 reports a single indexed study location in Other, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01046825 about?
NCT01046825 is a clinical study titled "Mature B-Cell Lymphoma And Leukemia Study III". This is a phase III clinical trial using risk-adapted therapy. Treatment outcomes for children with B-cell NHL are excellent. Further improvements in outcome will likely be achieved through more focused study of the biology of the tumors and prospective studies of the late effects of treatment. Towa...
What is the current status of trial NCT01046825?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2010-09-09. Estimated completion is 2027-08.
What conditions does trial NCT01046825 study?
This clinical trial studies the following conditions: Mature B-Cell Lymphoma.
What interventions are being tested in trial NCT01046825?
The interventions under investigation include: COPAD (DRUG), COP, COPD M3, CYM (DRUG), COP, COPADM8, CYVE (DRUG).
Who is sponsoring clinical trial NCT01046825?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01046825 being conducted?
This trial has 4 study locations across California, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01046825's enrollment target sits among peer trials
128 553rd of 2000 higher than 1,446 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI